Perceptic Raises $12M Seed
Perceptic, a London, UK-based company that provides an end-to-end AI platform for drug development, has raised $12 million in seed funding.
The round was led by Accel, with participation from Air Street Capital and Elder Gull.
The company intends to use the capital to scale its engineering capabilities, expand its customer base, and grow its presence within the United States market.
Founded by Tilman Flock, Martin Copes, and Zaki Trache, Perceptic develops an infrastructure-agnostic operating layer that unifies siloed pharmaceutical R&D workflows. The company utilizes a software-driven approach to unify pharmaceutical research and development workflows through traceable AI agents. Perceptic automates scientific due diligence, clinical trial indication selection, and data harmonization through the use of traceable AI agents.
Funding Details
Company Website: https://perceptic.com
Company: Perceptic
Raised: $12M
Round: Seed
Funding Date: June 1, 2026
Lead Investor: Accel
Additional Investors: Air Street Capital, Elder Gull
Software Category: AI for Drug Development